Evidence map›Paper›PMID 34521752›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

DNA damage-induced phosphorylation of CtIP at a conserved ATM/ATR site T855 promotes lymphomagenesis in mice.

Xiaobin S Wang, Demis Menolfi, Foon Wu-Baer, Marco Fangazio, Stefanie N Meyer, Zhengping Shao, Yunyue Wang, Yimeng Zhu, Brian J Lee, Verna M Estes and 6 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Key molecular DNA damage responses of human cells to radiation.Frontiers in cell and developmental biology · 2024
    Review
  5. Review
  6. Article
  7. Inactive PARP1 causes embryonic lethality and genome instability in a dominant-negative manner.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Xiaobin S WangInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Demis MenolfiInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Foon Wu-BaerInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Marco FangazioInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Stefanie N MeyerInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Zhengping ShaoInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Yunyue WangInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Yimeng ZhuInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.ORCID 0000-0003-3186-7697
Brian J LeeInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.ORCID 0000-0001-5550-1468
Verna M EstesInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Olivia M CupoInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Jean GautierInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Laura PasqualucciInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.ORCID 0000-0001-6819-7370
Riccardo Dalla-FaveraInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Richard BaerInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032.
Shan ZhaInstitute for Cancer Genetics, Vagelos College for Physicians and Surgeons, Columbia University, New York City, NY 10032; sz2296@columbia.edu.ORCID 0000-0002-6568-1818
Cancer Genetics (United States) · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
The Role of CTIP in Lymphocyte Development and LymphomagenesisP01CA174653 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RABADAN, RAUL · 2014 to 2024
$17.6M
DNA Repair and Genomic Instability in Cancer Development and TherapyR35CA197606 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GAUTIER, JEAN · 2015 to 2021
$5.7M
The role of ATM in the suppression of lymphoid malignancyR01CA158073 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2011 to 2026
$5.7M
The structural function of ATR in development, oncogenesis and cancer therapyR01CA215067 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZHA, SHAN · 2017 to 2021
$1.9M
The catalytic and non-catalytic functions of PARP1 in cancer biologyR01CA226852 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZHA, SHAN · 2018 to 2022
$1.8M
The BARD1 tumor suppressor and breast cancerR01CA172272 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BAER, RICHARD J · 2013 to 2017
$1.7M
Clinical and Translational Science AwardTL1TR000082 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$732k
NCATS NIH HHS TL1 TR000082NCATS NIH HHS UL1 TR001873NCI NIH HHS P01 CA174653NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA158073NCI NIH HHS R01 CA172272NCI NIH HHS R01 CA215067NCI NIH HHS R01 CA226852NCI NIH HHS R35 CA197606
6 · The paper itself

Abstract

CtIP is a DNA end resection factor widely implicated in alternative end-joining (A-EJ)-mediated translocations in cell-based reporter systems. To address the physiological role of CtIP, an essential gene, in translocation-mediated lymphomagenesis, we introduced the T855A mutation at murine CtIP to nonhomologous end-joining and Tp53 double-deficient mice that routinely succumbed to lymphomas carrying A-EJ-mediated IgH-Myc translocations. T855 of CtIP is phosphorylated by ATM or ATR kinases upon DNA damage to promote end resection. Here, we reported that the T855A mutation of CtIP compromised the neonatal development of

Indexed as

AnimalsAtaxia Telangiectasia Mutated ProteinsCarrier ProteinsCell Cycle ProteinsDNA DamageG2 Phase Cell Cycle CheckpointsLymphomaMiceMutationPhosphorylationTranslocation, GeneticAtaxia Telangiectasia Mutated ProteinsAtm protein, mouseAtr protein, mouseCarrier ProteinsCell Cycle ProteinsRBBP8 protein, mousealternative end-joiningcheckpointCtIPDNA damage responselymphomagenesis

Identifiers

PMID34521752
PMCPMC8463888
OpenAlexW3200681984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.